Business
MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's
MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nNEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions, Glaucoma and Parkinson's disease, today announced the issuance of Hong Kong patent HK1204364 covering the use of MANF as a treatment for beta cell disorders, including Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome. This patent extends exclusivity for MANF in the treatment of diabetes and Wolfram's Syndrome in Hong Kong into 2032.\n Multiple research groups have published data demonstrating the therapeutic potential of MANF in treating diabetes, including data published in the peer-reviewed scientific journal Cell Reports entitled \"MANF Is Indispensable for the Proliferation and Survival of Pancreatic Cells.\" The study demonstrated the therapeutic benefit of MANF in protecting and restoring pancreatic beta cells in vitro and in vivo in animal models of diabetes. The study's authors determined \"lack of MANF in vivo in mouse leads to chronic unfolded protein response (UPR) activation in pancreatic islets. Importantly, MANF protein enhanced cell proliferation in vitro and overexpression of MANF in the pancreas of diabetic mice enhanced cell regeneration. We demonstrate that MANF specifically promotes cell proliferation and survival, thereby constituting a therapeutic candidate for cell protection and regeneration.\" Wolfram's Syndrome is a rare, genetic pediatric condition characterized by Type-1 diabetes, blindness due to optic atrophy, deafness and neurodegeneration that affects an estimated 20,000 patients worldwide, including 1,000 in the United States. Cellular degeneration occurs in Wolfram's Syndrome due to stress of the endoplasmic reticulum (ER), a structure in cells where newly formed proteins are folded into their functional shapes. MANF is an ER-resident chaperone responsible for improving protein folding caused by stress. Wolfram's patients typically develop Type-1 diabetes in early childhood due to beta cell degeneration. MANF Therapeutics is preparing to restart IND-enabling development of MANF in 2018. MANF has t...